The role of entacapone in the management of Parkinson's disease

被引：4

作者：

Brooks, DJ ^{[1
]}

Forsyth, D

Playfer, JR

Williams, AC

机构：

[1] Hammersmith Hosp, Imperial Coll, Sch Med, London W12 0NN, England

[2] Addenbrookes NHS Trust Hosp, Cambridge, England

[3] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England

[4] Queen Elizabeth Hosp, Dept Neurosci, Birmingham B15 2TH, W Midlands, England

来源：

HOSPITAL MEDICINE | 2000年 / 61卷 / 04期

关键词：

D O I：

10.12968/hosp.2000.61.4.1315

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

Catechol-O-methyltransferase (COMT) inhibition is an important advance in the treatment of parkinson's disease. This consensus statement provides guidelines for the optimal use of the only currently available COMT inhibitor, entacapone (Comtess(R) Orion Pharma (UK) Ltd, Newbury, Berkshire).

引用

页码：267 / 271

页数：5

共 14 条

[1]

*AD INT LTD, 1999, PROD MON AD INT LTD

[2]

Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease - A multicenter 5-year study [J].

Block, G ;

Liss, C ;

Reines, S ;

Irr, J ;

Nibbelink, D ;

Aarli, J ;

Aguilar, M ;

Ahrens, S ;

Bakheit, A ;

Baumel, B ;

Bertoni, J ;

Capildeo, R ;

CastroCaldas, A ;

Deza, L ;

Donaldson, I ;

Franck, G ;

Fusillo, J ;

Gauthier, S ;

Gershanik, O ;

Granerus, AK ;

Hauser, RA ;

Hennessey, K ;

Hutton, JT ;

Joffe, R ;

Koller, W ;

Last, B ;

LeWitt, P ;

Mamoli, B ;

Manyam, B ;

Mark, M ;

Nakano, K ;

Nausieda, P ;

Otero, E ;

Paulson, G ;

Pinter, M ;

Reich, S ;

Rodnitzky, R ;

Sage, J ;

Sampaio, C ;

Smith, B ;

Teravainen, H ;

Tetrud, J ;

Tolosa, E ;

Ulm, G ;

Valesco, F .

EUROPEAN NEUROLOGY, 1997, 37 (01) :23-27

[3]

Dupont E, 1996, ACTA NEUROL SCAND, V93, P14

[4]

MOTOR FLUCTUATIONS IN PARKINSONS-DISEASE - CENTRAL PATHOPHYSIOLOGICAL MECHANISMS .1. [J].

FABBRINI, G ;

MOURADIAN, MM ;

JUNCOS, JL ;

SCHLEGEL, J ;

MOHR, E ;

CHASE, TN .

ANNALS OF NEUROLOGY, 1988, 24 (03) :366-371

[5]

Fahn S., RECENT DEV PARKINSON, V2, P153, DOI DOI 10.1002/ANA.410220556

[6]

Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: Effects on hemodynamics and catecholamine metabolism in healthy volunteers [J].

Illi, A ;

Sundberg, S ;

OjalaKarlsson, P ;

Scheinin, M ;

Gordin, A .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (04) :450-457

[7]

Simultaneous inhibition of catecholamine-O-methylation by entacapone and neuronal uptake by imipramine: Lack of interactions [J].

Illi, A ;

Sundberg, S ;

OjalaKarlsson, P ;

Scheinin, M ;

Gordin, A .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 51 (3-4) :273-276

[8]

Kieburtz K, 1997, ANN NEUROL, V42, P747

[9]

KOLLER WC, 1990, NEUROLOGY, V40, P40

[10]

Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease [J].

Lees, AJ .

BRITISH MEDICAL JOURNAL, 1995, 311 (7020) :1602-1607

← 1 2 →